ANI Pharmaceuticals, Inc. $ANIP Shares Bought by Bank of America Corp DE

Key Points

• Bank of America increased its ANI Pharmaceuticals stake by 229.4% in the first quarter, bringing its holdings to 150,532 shares valued at approximately $11.6 million. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals reported quarterly EPS of $2.21, beating estimates of $2.04, while revenue rose 25.8% year over year to $266.04 million. The company issued fiscal 2026 EPS guidance of $9.19–$9.69.
• ANIP shares opened at $75.35, below their 50-day and 200-day moving averages. Analysts maintain a “Moderate Buy” consensus, though several recently downgraded the stock or lowered price targets; the average target is $105.83.

Bank of America Corp DE increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 229.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 150,532 shares of the specialty pharmaceutical company's stock after acquiring an additional 104,828 shares during the period. Bank of America Corp DE owned approximately 0.66% of ANI Pharmaceuticals worth $11,576,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ANIP. Vanguard Group Inc. increased its position in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock valued at $103,022,000 after buying an additional 27,598 shares in the last quarter. State Street Corp lifted its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company's stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG boosted its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock worth $43,399,000 after buying an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock valued at $40,843,000 after purchasing an additional 43,523 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

ANIP opened at $75.35 on Friday. The business has a fifty day simple moving average of $80.36 and a 200-day simple moving average of $78.88. The firm has a market cap of $1.73 billion, a PE ratio of 16.24 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company earned $1.80 EPS. The business's revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Guggenheim reduced their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Zacks Research downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Canaccord Genuity Group decreased their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Finally, Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $105.83.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 18,987 shares of company stock worth $1,546,405. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source